Related Experiment Videos
[Treatment for Hodgkin's disease]
Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 31, 2000
Summary
Radiation therapy was the historical standard for localized Hodgkin lymphoma (HL). Chemotherapy, including ABVD, is now preferred due to efficacy and reduced toxicity, with newer regimens showing promise for advanced HL.
Area of Science:
- Oncology
- Hematology
- Cancer Therapy
Context:
- Hodgkin lymphoma (HL) treatment has evolved significantly.
- Historically, radiation therapy was the primary treatment for localized HL.
- Concerns regarding late adverse effects of radiation have driven a shift towards systemic therapies.
Purpose:
- To review the current treatment landscape for Hodgkin lymphoma.
- To compare different chemotherapy regimens and their efficacy.
- To outline treatment strategies for refractory or relapsed disease.
Summary:
- Chemotherapy, particularly ABVD, is replacing radiation for localized HL due to comparable efficacy and lower toxicity.
- Advanced stage HL treatment favors ABVD over MOPP, with intensified regimens like escalated BEACOPP and Stanford V showing promising early results.
- High-dose chemotherapy with autologous stem cell rescue is the recommended approach for patients with primary refractory or relapsed HL post-chemotherapy.
Impact:
- This review provides an updated overview of Hodgkin lymphoma treatment strategies.
- It highlights the shift towards chemotherapy and discusses advanced treatment options.
- The information is crucial for oncologists and hematologists managing HL patients.